Table 3.

FUTURE-2 trial results

Endpoint	Percent improvement secukinumab 300 mg n = 100	Percent improvement secukinumab 150 mg n = 100	Percent improvement secukinumab 75 mg n = 99	Placebo n = 98 (%)	P value
Week 24 (total n = 397)
ACR20 score	54.0	51	29.3	15.3	P < 0.001 for 300 and 150 mg groups P = 0.0399 for 75 mg group
ACR50 score	35.0	35.0	18.2	7.1	P < 0.001 for all comparisons
ACR70 score	18.8		16.8	2.0	P < 0.001 for all comparisons
Week 52 (total n = 335)
ACR20 score	73	73	67	–	–
ACR50 score	50	44	40	–	–
ACR70 score	27	23	21	–	–

ACR20 American College of Rheumatology 20 response, ACR50 American College of Rheumatology 50 response, ACR70 American College of Rheumatology 70 response